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Chronic kidney disease (CKD) is one of the
fastest growing global causes of death,
estimated to rank among the top five by
2040 (Foreman et al, 2018). This illustrates
current pitfalls in diagnosis and manage-
ment of CKD. Advanced CKD requires renal
function replacement by dialysis or trans-
plantation. However, earlier CKD stages,
even when renal function is still normal,
are already associated with an increased
risk of premature death (Perez-Gomez
et al, 2019). Thus, novel approaches to
diagnose and treat CKD are needed. The
histopathological hallmark of CKD is
kidney fibrosis, which is closely associated
with local inflammation and loss of kidney
parenchymal cells. Thus, kidney fibrosis is
an attractive process to develop tests
allowing an earlier diagnosis of CKD and
represents a potential therapeutic target
to slow CKD progression or promote
regression.
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F rom the diagnostic point of view, toolsfor accurately staging CKD and for dif-ferentiating ongoing active kidney
injury potentially responding to current ther-
apies from therapy-resistant residual fibrosis
are suboptimal. Thus, although CKD risk
categories are well defined and internation-
ally accepted, they are based on estimated
glomerular filtration rate (GFR) and assess-
ment of albuminuria. GFR estimation is
notoriously inaccurate, and there is no
consensus on the risk associated with GFR-
based category G3a, the most common CKD
stage (González-Rinne et al, 2019). Addi-
tionally, pathological albuminuria is found
both in active ongoing glomerular injury
and in residual glomerular sclerosis. A
kidney biopsy may help differentiate
between active and inactive kidney diseases,
but it is invasive and only provides informa-
tion on a minuscule kidney sample, that
may or may not represent the whole kidney.
Thus, ongoing efforts aim at developing
non-invasive tools to assess global kidney
fibrosis in the clinic. The most advanced
approaches are urine proteomics and kidney
magnetic resonance imaging (MRI), while
molecular imaging of fibrosis-specific
proteins is still preclinical (Selby et al, 2018;
Magalhães et al, 2017; Baues et al, 2019
online).
From the therapeutic point of view, there
is an ongoing discussion on the active
contribution of fibrosis to CKD progression,
and thus, on whether targeting fibrosis may
effectively slow or even reverse CKD; or on
the contrary, if fibrosis represents a
common end-stage of any CKD, its targeting
would not alter the natural history of CKD.
Finally, fibrosis may even be a healing,
beneficial process (Djudjaj & Boor, 2019).
Clinical evidence on the active role of
fibrosis allows several interpretations. On
one hand, clinical trials exploring
approaches directly targeting fibrosis have
so far failed (Ramos et al, 2020). On the
other hand, renin–angiotensin system (RAS)
blockade, which constitutes the best estab-
lished nephroprotective strategy, interferes
with fibrosis along with other pathogenic
processes.
In the present issue of EMBO Molecular
Medicine, Buhl et al (2020) conclusively
demonstrate that deregulated hyperactivity
of the platelet-derived growth factor recep-
tor-b (PDGFR-b) in mouse renal mesenchy-
mal cells leads to pathological proliferation
of mesangial cells and interstitial fibroblasts.
It further leads to a phenotype switch
toward myofibroblasts driving mesangial
sclerosis, interstitial fibrosis, decreased GFR,
and renal anemia (Buhl et al, 2020). In
short, PDGFR-b overactivity in renal
mesenchymal cells caused CKD. This
preclinical model is clinically relevant since
increased expression of PDGFR-b by kidney
mesenchymal cells is found in human CKD,
and the features of this murine model over-
lap with those of human CKD. PDGFR-b
forms homodimeric or heterodimeric recep-
tors for PDGF-B and PDGF-D, and targeting
either PDGFR-b, PDGF-B, or PDGF-D has
been protective in diverse preclinical models
of kidney disease. The originality of the
present study is fourfold:
First, hyperactivity of a single receptor in
mesenchymal cells only drove glomerular
and interstitial fibrosis, and this preceded
tubular atrophy and interstitial inflammation
in the absence of hypertension, albuminuria
or hematuria (Fig 1). Thus, the study
demonstrates that fibrosis itself is patho-
genic and may drive the full spectrum of
CKD even in the absence of primary insult
to parenchymal kidney cells or without
engagement of common drivers of clinical
CKD progression (proteinuria, hematuria,
hypertension).
Second, PDGFR-b hyperactivity commit-
ted erythropoietin (EPO)-producing intersti-
tial cells to a fibrogenic phenotype at the
expense of EPO production, thus driving
anemia. This identifies PDGFR-b as a nega-
tive regulator of physiological endocrine
kidney EPO, which differs from the tumor
microenvironment situation, where PDGF-
BB signaling via PDGFR-b in local stromal
cells induces EPO production. This may
promote tumor growth through paracrine
stimulation of tumor angiogenesis and by
endocrine stimulation of extramedullary
hematopoiesis (Xue et al, 2011). This
finding opens the door to adjunctive thera-
pies for uremic anemia that target PDGFR-b
hyperactivity in diseased kidneys. In this
regard, it is significant that imatinib, an
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inhibitor of multiple receptor kinases,
including PDGFR-b, reversed anemia in mice
with mesenchymal cell PDGFR-b hyperacti-
vation (Buhl et al, 2020). Indeed, anemia is
a common adverse effect of imatinib used
for cancer treatment.
Third, myofibroblast cell number and
interstitial fibrosis (but not glomerular
sclerosis) abnormalities were reversed by
imatinib. However, whether there is an
immediate clinical translation of this obser-
vation remains to be demonstrated. Indeed,
the impact of imatinib on GFR was not
addressed, and therapeutic use for human
disease may be limited by the lack of impact
on glomerular fibrosis, since glomerular
health is a key determinant of GFR. Addi-
tionally, at the doses currently used in
human cancer, imatinib has been associated
with an increased incidence of acute kidney
injury and chronic loss of GFR. Further
research is thus warranted to define poten-
tially nephroprotective imatinib regimens or
to identify the specific additional kinases
targeted by imatinib that may preclude
nephroprotection in humans. While PDGFR-
b targeting with current tools may have limi-
tations, Buhl et al identified the early
signaling pathways engaged by PDGFR-b
overactivity in mesenchymal kidney cells.
Interferon-related signaling and JAK/STAT
signaling were prominently represented.
However, JAK/STAT signaling was not
involved in kidney fibrosis in this model.
This is important information since the JAK/
STAT inhibitor baricitinib decreased albu-
minuria in diabetic kidney disease trials,
although clinical development appears to
have stalled.
Finally, a pure kidney fibrosis model may
help set up kidney imaging or proteomics/
metabolomics fingerprints to assess kidney
fibrosis that are only modified by fibrosis,
without being modified by concomitant
kidney parenchymal cell injury or inflamma-
tion that represent confounding factors
usually concurring with fibrosis in the clinic
and in most available preclinical models. As
an example, late gadolinium enhancement,
long thought to represent irreversible scar
tissue in cardiac MRI, is now also considered
to be present during cardiac inflammation.
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Figure 1. Clinical CKD progression versus kidney fibrosis and subsequent CKD progression induced by mesenchymal cell PDGFR-b hyperactivity.
(A) A simplified view of clinical CKD progression is provided. Diverse insults may lead to primary injury of diverse kidney cell types, setting in motion clinical manifestation and
processes (e.g., hypertension, hematuria, proteinuria) that amplify injury, usually by recruiting inflammatory mediators, leading to loss of parenchymal renal cells and
kidney fibrosis. Uremic, EPO-deficient anemia is a feature of advanced CKD. (B) Experimental kidney fibrosis induced by mesenchymal cell PDGFR-b hyperactivity. Kidney
fibrosis is the earliest manifestation of kidney injury, predisposes to CKD progression in response to other insults, and is associated with early anemia. Of note, fibrosis clearly
precedes other features of CKD such as inflammation and parenchymal cell injury and is not associated with hypertension, hematuria, or proteinuria. The potential uses of
this new tool are indicated.
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